FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy – STAT

1. FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy STAT
2. Krystal’s Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease FiercePharma
3. Rare Skin Blistering Condition Gets First Drug Approved Medpage Today
4. Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB). Business Wire
5. FDA Approves First-Ever Topical Gene Therapy Medscape
6. View Full Coverage on Google News

Read original article here